NCT02116257 is a NA clinical trial of Propacetamol in PONV, sponsored by Yonsei University.

Who is sponsoring NCT02116257?

NCT02116257 is sponsored by Yonsei University.

What drugs are being tested in NCT02116257?

Interventions in NCT02116257: Propacetamol, PCA regimen.

What condition does NCT02116257 study?

NCT02116257 studies PONV, Propacetamol.

Is NCT02116257 still recruiting?

NCT02116257 is currently completed. Last updated 23 June 2015.

Last reviewed 2015-06-23 · How we verify

NCT02116257

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Opioid-sparing Effect and Reduced PONV Using Propacetamol in PCA Among Patients With High Risk of PONV

Completed NA Last updated 23 June 2015

What this trial tests

NA trial testing Propacetamol in PONV in 108 participants. Completed in 1 March 2015.

Timeline

1 November 2013

Primary endpoint
1 March 2015

1 March 2015

Quick facts

Lead sponsor	Yonsei University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	prevention
Enrollment	108
Start date	1 November 2013
Primary completion	1 March 2015
Estimated completion	1 March 2015
Sites	1 location across South Korea

Drugs / interventions tested

Propacetamol (PROPACETAMOL) — full drug profile →
PCA regimen

Conditions studied

PONV — all drugs for PONV →
Propacetamol — all drugs for Propacetamol →

Sponsor

Yonsei University

Who can join

Adults 20 to 65, female only, with PONV or Propacetamol. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Incidence of PONV
Time frame: from immediate postop to 24 hours after the surgery
Incidence of postoperative nausea, vomiting - Number of events

Sponsor's own description

While Patient-controlled analgesia (PCA) has the advantage of effectively reducing the degree of postoperative pain, it can also affect the patient's outcome by several adverse effects such as postoperative nausea and vomiting (PONV). Especially for high risk group of patients for PONV, the ideal regimen for sufficient analgesia with minimal adverse effect needs to be sought. Propacetamol is known for its effective, rapid analgesia, opioid-sparing effect, and is used widely for post operative pain management. This study aims to see the opioid-sparing effect and the degree of PONV when propacetamol is added to PCA for high risk PONV patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Propacetamol

Trials testing the same drug.

NCT02577068 — Combination Effect of Nefopam With Propacetamol for Postoperative Pain After Thyroidectomy · NA · completed
NCT02515188 — The Effect of Additional Propacetamol Infusion on Post Procedural Outcome and Opioid Consumption During Catheter Ablatio · NA · completed

Other recruiting trials for PONV

Currently open trials in the same condition.

NCT07515027 — Electroacupuncture Plus 5-HT3 Receptor Inhibitor for PONV Prevention in High-Risk Patients Undergoing Thoracoscopic Lung · NA · recruiting
NCT07176676 — Aromatherapy Treatment With Lavender Essential Oil to Reduce Post-Operative Nausea and Vomiting (PONV) · NA · active not recruiting
NCT07051109 — Dual-chamber Patient-controlled Analgesia for Postoperative Recovery · NA · recruiting
NCT03783182 — Betamethasone (Betapred®) as Premedication for Reducing Postoperative Vomiting and Pain After Tonsillectomy · Phase 4 · recruiting
NCT03187535 — Effect of TEAS on PONV After Spinal Surgery · NA · recruiting

Other Yonsei University trials

Trials by the same sponsor.

NCT07547592 — Gemcitabine and Docetaxel With or Without Bevacizumab (Onbevzi) for Soft Tissue Sarcoma · Phase 2 · not yet recruiting
NCT07524101 — Moderate-Intensity Statin Plus Ezetimibe in CKD and ASCVD · NA · not yet recruiting
NCT07506629 — Adductor Canal Block Methods in Bilateral Total Knee Arthroplasty · NA · not yet recruiting
NCT07515716 — Effects of High Flow Humidified Oxygen on Umbilical Artery Acid-base Balance in Cesarean Section Under Spinal Anesthesia · NA · not yet recruiting
NCT07507188 — Collaborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and Amivantamab Plus Chemotherapy in Patients · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02116257 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yonsei University
Last refreshed: 23 June 2015

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02116257.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing